Dosing & Administration

Oral and IV Monotherapy Dosing
With BAXDELA® (delafloxacin)

Oral or IV q12h dosing

Baxdela dosing table

No Oral Dosage Adjustment Required Due To:

BAXDELA is not recommended in patients with End Stage Renal Disease (ESRD) (eGFR >15 mL/min/1.73 m2), including patients on hemodialysis, due to insufficient information for dosing recommendations.

Fixed-Dosage Adjustment in IV Formulation for Patients with Severe Renal Impairment (eGFR 15-29 mL/min/1.73 m2)

  • 200 mg IV q12h


  • 200 mg IV q12h, then switch to a 450-mg BAXDELA tablet orally q12h at the discretion of the physician
BAXDELA® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.